Maze Therapeutics (NASDAQ:MAZE) Posts Earnings Results, Misses Estimates By $0.02 EPS

Maze Therapeutics (NASDAQ:MAZE) announced its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02), FiscalAI reports. The firm had revenue of $20.00 million for the quarter.

Maze Therapeutics Trading Down 2.4%

Shares of NASDAQ MAZE traded down $0.64 during trading on Thursday, reaching $26.33. The company had a trading volume of 201,276 shares, compared to its average volume of 730,519. Maze Therapeutics has a twelve month low of $8.24 and a twelve month high of $53.65. The stock has a 50-day moving average price of $34.19 and a two-hundred day moving average price of $38.04. The stock has a market capitalization of $1.31 billion, a PE ratio of -10.41 and a beta of 2.50.

Insider Buying and Selling

In related news, CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total value of $441,900.00. Following the completion of the transaction, the chief marketing officer owned 15,000 shares of the company’s stock, valued at approximately $441,900. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at approximately $266,461.11. This trade represents a 41.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 70,000 shares of company stock worth $2,955,775. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC raised its holdings in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after purchasing an additional 362,060 shares during the period. Woodline Partners LP grew its position in shares of Maze Therapeutics by 10.0% in the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after purchasing an additional 94,529 shares during the period. Marshall Wace LLP grew its position in shares of Maze Therapeutics by 9.0% in the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after purchasing an additional 69,771 shares during the period. Finally, ArrowMark Colorado Holdings LLC increased its stake in Maze Therapeutics by 40.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company’s stock valued at $31,793,000 after purchasing an additional 222,251 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Guggenheim boosted their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, HC Wainwright raised their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.